Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK ‐rearranged non‐small cell lung cancer
Cancer Science · 2023
DOI: 10.1111/cas.15958 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Science, 2023. Verfasst von Chihiro Ando und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Lung Cancer Society.
Abstract (Originalsprache)
Gilteritinib is a multitarget tyrosine kinase inhibitor (TKI), approved for the treatment of FLT3‐mutant acute myeloid leukemia, with a broad range of activity against several tyrosine kinases including anaplastic lymphoma kinase (ALK). This study investigated the efficacy of gilteritinib against ALK ‐rearranged non‐small cell lung cancers (NSCLC). To this end, we assessed the effects of gilteritinib on cell proliferation, apoptosis, and acquired resistance responses in several ALK ‐rearranged NSCLC cell lines and mouse xenograft tumor models and compared its efficacy to alectinib, a standard ALK inhibitor. Gilteritinib was significantly more potent than alectinib, as it inhibited cell proliferation at a lower dose, with complete attenuation of growth observed in several ALK ‐rearranged NSCLC cell lines and no development of drug tolerance. Immunoblotting showed that gilteritinib strongly suppressed phosphorylated ALK and its downstream effectors, as well as mesenchymal–epithelial transition factor (MET) signaling. By comparison, MET signaling was enhanced in alectinib‐treated cells. Furthermore, gilteritinib was found to more effectively abolish growth of ALK ‐rearranged NSCLC xenograft tumors, many of which completely receded. Interleukin‐15 (IL‐15) mRNA levels were elevated in gilteritinib‐treated cells, together with a concomitant increase in the infiltration of tumors by natural killer (NK) cells, as assessed by immunohistochemistry. This suggests that IL‐15 production along with NK cell infiltration may constitute components of the gilteritinib‐mediated antitumor responses in ALK ‐rearranged NSCLCs. In conclusion, gilteritinib demonstrated significantly improved antitumor efficacy compared with alectinib against ALK ‐rearranged NSCLC cells, which can warrant its candidacy for use in anticancer regimens, after further examination in clinical trial settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
- Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
- Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
- Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
ORCID-Profile: Eiki Ichihara, Hirohisa Kano, Go Makimoto, Toshio Kubo, Kadoaki Ohashi
Förderung
- Japan Lung Cancer Society
Zitieren
APA
Ando, C., Ichihara, E., Nishi, T., Morita, A., Hara, N., Takada, K., Nakasuka, T., Watanabe, H., Kano, H., Nishii, K., Makimoto, G., Kondo, T., Ninomiya, K., Fujii, M., Kubo, T., Ohashi, K., Matsuoka, K. I., Hotta, K., Tabata, M., …, & Kiura, K. (2023). Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK ‐rearranged non‐small cell lung cancer. Cancer Science. https://doi.org/10.1111/cas.15958
Vancouver
Ando C, Ichihara E, Nishi T, Morita A, Hara N, Takada K, et al. Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK ‐rearranged non‐small cell lung cancer. Cancer Science. 2023. doi:10.1111/cas.15958
BibTeX
@article{Ando2023,
author = {Ando, Chihiro and Ichihara, Eiki and Nishi, Tatsuya and Morita, Ayako and Hara, Naofumi and Takada, Kenji and Nakasuka, Takamasa and Watanabe, Hiromi and Kano, Hirohisa and Nishii, Kazuya and Makimoto, Go and Kondo, Takumi and Ninomiya, Kiichiro and Fujii, Masanori and Kubo, Toshio and Ohashi, Kadoaki and Matsuoka, Ken-Ichi and Hotta, Katsuyuki and Tabata, Masahiro and Maeda, Yoshinobu and Kiura, Katsuyuki},
title = {Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK ‐rearranged non‐small cell lung cancer},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15958}
}
EUVIMED